Last updated on June 2020

Phase II Trial of AZD6738 Alone and in Combination With Olaparib

Brief description of study

This phase II trial studies how well ATR kinase inhibitor AZD6738 works alone or in combination with olaparib in treating participants with renal cell carcinoma, urothelial carcinoma, all pancreatic cancers, or other solid tumors excluding clear cell ovarian cancer that have spread to nearby tissue or lymph nodes or other parts of the body. ATR kinase inhibitor AZD6738 and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not known if giving ATR kinase inhibitor AZD6738 with or without olaparib may work better in treating participants with solid tumors.

Detailed Study Description


I. To assess objective response rate (ORR) of ATR kinase inhibitor AZD6738 (AZD6738) monotherapy and AZD6738 + olaparib by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.


I. To determine the median duration of response (DOR) in each study arm. II. To determine the median progression-free survival and progression-free survival rate at 6 and 12 months in each study arm.

III. To further characterize the safety and tolerability profile of AZD6738 alone and in combination with olaparib.

Clinical Study Identifier: NCT03682289

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.